Cargando…

Celiac disease serology and gut microbiome following proton pump inhibitor treatment

BACKGROUND: Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals. Studies have pointed to a rising prevalence of celiac disease in recent decades. Changes in diet and use of medication that may impact the g...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Sophie, Lebwohl, Benjamin, Abrams, Julian A., Green, Peter H.R., Freedberg, Daniel E., Alaedini, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458245/
https://www.ncbi.nlm.nih.gov/pubmed/32871870
http://dx.doi.org/10.1097/MD.0000000000021488
_version_ 1783576155963523072
author Jang, Sophie
Lebwohl, Benjamin
Abrams, Julian A.
Green, Peter H.R.
Freedberg, Daniel E.
Alaedini, Armin
author_facet Jang, Sophie
Lebwohl, Benjamin
Abrams, Julian A.
Green, Peter H.R.
Freedberg, Daniel E.
Alaedini, Armin
author_sort Jang, Sophie
collection PubMed
description BACKGROUND: Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals. Studies have pointed to a rising prevalence of celiac disease in recent decades. Changes in diet and use of medication that may impact the gut microbiome have been suggested as potential contributors. Exposure to proton pump inhibitors (PPIs) was recently found to be associated with an increased risk for subsequent diagnosis of celiac disease. We aimed to investigate potential mechanisms for this link by examining the relationship between PPI use and gluten-related immune responses in the context of changes in gut microbiome. METHODS: We performed a post hoc analysis of blood and fecal samples from a recent randomized trial in order to assess the potential association between PPI use and development of celiac disease serology in conjunction with alterations in gastrointestinal microbial composition. The study included 12 healthy participants who were administered a PPI (Omeprazole; 40 mg twice daily) for 4 or 8 weeks. RESULTS: The analysis did not reveal an overall significant change in levels of serologic markers of celiac disease for the study cohort in response to PPI treatment. However, one individual developed a marked increase in the celiac disease-specific autoantibody response to transglutaminase 2 in conjunction with enhanced immune reactivity to gluten during the trial. Genotyping revealed positivity for the celiac disease-associated HLA-DQ2 and -DQ8 alleles. Furthermore, the observed elevation in antibody responses was closely associated with a sharp increase in fecal abundance of bacteria of the order Actinomycetales. CONCLUSIONS: The results of this exploratory analysis support further investigation of molecular mechanisms involved in the contribution of PPIs to celiac disease risk through the potential enhancement of gluten immunopathology and changes in gut microbial population.
format Online
Article
Text
id pubmed-7458245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74582452020-09-11 Celiac disease serology and gut microbiome following proton pump inhibitor treatment Jang, Sophie Lebwohl, Benjamin Abrams, Julian A. Green, Peter H.R. Freedberg, Daniel E. Alaedini, Armin Medicine (Baltimore) 4500 BACKGROUND: Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals. Studies have pointed to a rising prevalence of celiac disease in recent decades. Changes in diet and use of medication that may impact the gut microbiome have been suggested as potential contributors. Exposure to proton pump inhibitors (PPIs) was recently found to be associated with an increased risk for subsequent diagnosis of celiac disease. We aimed to investigate potential mechanisms for this link by examining the relationship between PPI use and gluten-related immune responses in the context of changes in gut microbiome. METHODS: We performed a post hoc analysis of blood and fecal samples from a recent randomized trial in order to assess the potential association between PPI use and development of celiac disease serology in conjunction with alterations in gastrointestinal microbial composition. The study included 12 healthy participants who were administered a PPI (Omeprazole; 40 mg twice daily) for 4 or 8 weeks. RESULTS: The analysis did not reveal an overall significant change in levels of serologic markers of celiac disease for the study cohort in response to PPI treatment. However, one individual developed a marked increase in the celiac disease-specific autoantibody response to transglutaminase 2 in conjunction with enhanced immune reactivity to gluten during the trial. Genotyping revealed positivity for the celiac disease-associated HLA-DQ2 and -DQ8 alleles. Furthermore, the observed elevation in antibody responses was closely associated with a sharp increase in fecal abundance of bacteria of the order Actinomycetales. CONCLUSIONS: The results of this exploratory analysis support further investigation of molecular mechanisms involved in the contribution of PPIs to celiac disease risk through the potential enhancement of gluten immunopathology and changes in gut microbial population. Lippincott Williams & Wilkins 2020-08-28 /pmc/articles/PMC7458245/ /pubmed/32871870 http://dx.doi.org/10.1097/MD.0000000000021488 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4500
Jang, Sophie
Lebwohl, Benjamin
Abrams, Julian A.
Green, Peter H.R.
Freedberg, Daniel E.
Alaedini, Armin
Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title_full Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title_fullStr Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title_full_unstemmed Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title_short Celiac disease serology and gut microbiome following proton pump inhibitor treatment
title_sort celiac disease serology and gut microbiome following proton pump inhibitor treatment
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458245/
https://www.ncbi.nlm.nih.gov/pubmed/32871870
http://dx.doi.org/10.1097/MD.0000000000021488
work_keys_str_mv AT jangsophie celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment
AT lebwohlbenjamin celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment
AT abramsjuliana celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment
AT greenpeterhr celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment
AT freedbergdaniele celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment
AT alaediniarmin celiacdiseaseserologyandgutmicrobiomefollowingprotonpumpinhibitortreatment